Clinical Trials Logo

Marijuana Abuse clinical trials

View clinical trials related to Marijuana Abuse.

Filter by:

NCT ID: NCT04083261 Completed - Clinical trials for New York Medical Marijuana Program Qualifying Conditions

Pharmacogenetic Variation: Factors That May Affect the Efficacy and Safety of Medical Marijuana

Start date: July 11, 2019
Phase:
Study type: Observational

The primary purpose of this research is to identify genetic factors that may affect the efficacy and safety of medical marijuana, regardless of condition. The pharmacogenomics test detects DNA variants, which may affect the way drugs work and are metabolized in the body and/or detect potential side effects.

NCT ID: NCT04060602 Completed - Cannabis Use Clinical Trials

Personalized Feedback Intervention to Reduce Risky Cannabis Use.

Start date: September 3, 2019
Phase: N/A
Study type: Interventional

The purpose of this project is to determine whether participants who receive a personalized feedback report and educational materials about risky cannabis use will be less likely to report risky cannabis use at follow-up compared to participants who only received educational materials.

NCT ID: NCT04055662 Completed - Clinical trials for Cannabis Use, Opioid Consumption

A Comparison of Post-Operative Analgesia Requirements In Recreational Cannabis Users Versus Cannabis Naïve Inflammatory Bowel Disease Patients

Start date: August 1, 2019
Phase:
Study type: Observational

Cannabis is a drug that is widely used for recreational purpose. In most patients undergoing surgery, opioids are the most widely used mode of pain relief, during and following surgery. Anecdotally it has been observed that cannabis users required unexpectedly high doses of opioids. The purpose of this study is to compare opioid requirements between cannabis users and non- users after the surgery. Currently, post-operative opioid doses are determined based on various patient factors such as pre-operative opioid use, patient weight, age and sensitivity to opioids during surgery. Patients' requirements may be underestimated and opioid regimens need to be escalated in the first 24 hours in order to alleviate uncontrolled pain in cannabis users. Better understanding of the impacts of cannabis use on post-operative opioid requirements would help the Acute Pain Service optimize post-operative pain management for patients who use cannabis pre-operatively.

NCT ID: NCT04042545 Recruiting - Quality of Life Clinical Trials

Safety and Efficacy of Inhaled Cannabis For the Uncontrolled Pain Relief in Patients With Advanced Cancer

PLENITUDE
Start date: July 30, 2020
Phase: Phase 2
Study type: Interventional

This phase 2 multicenter clinical trial assess the safety and efficacy of inhaled PPP001 to relieve the pain in 78 advanced cancer patients with uncontrolled symptoms. This is a 4-week treatment period study followed by an open label period of 1 year.

NCT ID: NCT03994926 Terminated - Clinical trials for Cannabis Intoxication

Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment

Start date: February 3, 2020
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine if an eye tracking impairment sensor can detect cannabis-induced impairment after using cannabis.The overall objective is to correlate measures collected from the eye tracking sensor with measures related to cannabis impairment (e.g., plasma THC levels, self-reported cannabis subjective effects, cognitive effects).

NCT ID: NCT03994640 Completed - Clinical trials for Temporomandibular Disorder

Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With TMD

Start date: January 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Evaluation of myorelaxant effect of cannabis cream.compared to placebo cream in topical skin application in patients with TMD

NCT ID: NCT03987347 Withdrawn - Cannabis Use Clinical Trials

Health Condition of Cannabis Consumers in the Canadian Population

Start date: December 1, 2020
Phase:
Study type: Observational

This study evaluates the health condition and its evolution with time of Cannabis consumers in the Canadian population.

NCT ID: NCT03980561 Completed - Clinical trials for Cannabis Use Disorder

UH3 Varenicline for Cannabis Use Disorder

Start date: January 31, 2020
Phase: Phase 2
Study type: Interventional

Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.

NCT ID: NCT03964974 Completed - Cannabis Use Clinical Trials

Reducing Cannabis Use for Sleep Among Adults Using Medical Cannabis

CannSleep
Start date: February 10, 2020
Phase: N/A
Study type: Interventional

As medical cannabis use becomes more common in the United States, it is essential to understand the ways in which adults who use medical cannabis perceive the benefits of cannabis use and to identify effective strategies to help them cope with these problems. Emerging data indicate that insomnia and/or use of cannabis for sleep are very common in medical cannabis patients. The present study will adapt and gather pilot data on the impact of a Cognitive Behavioral Therapy for insomnia (CBTi-CB) intervention on sleep- and cannabis-related outcomes in adults who use medical cannabis.

NCT ID: NCT03929835 Withdrawn - Clinical trials for Hidradenitis Suppurativa

Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa

Start date: September 1, 2020
Phase: Phase 2
Study type: Interventional

Hidradenitis Suppurativa (HS), is a chronic skin disease, manifested as inflamed areas of hair follicles around apocrine sweat glands found in areas most commonly the axillae, inguinal and anogenital regions. Patients experience great deal of physical pain as well as profound psychological problems. HS patients may also be prone to health complications and diseases. Treatment to date is limited and consist mainly of antibiotic administration and novel biological drug with up to 40% efficiency. Recently it was shown that cannabinoids reduces the folliculo pilosebaceous activity, most likely due to activating arachnoiditis, lipostat , anti-proliferative and anti-inflammatory agents and reduce inflammation inducing cytokines.